High-grade endometrial cancer survival (endometrioid to non-endometrioid histology comparison)

Purpose of Investigation: To analyze overall survival (OS) and disease-free survival (DFS) in a retrospective series of 125 patients with serous, clear cell, and high-grade endometrioid carcinoma having undergone complete treatment (primary surgery, oncology treatments, and follow up) at the present institution. Materials and Methods: All women with high-grade endometrial cancer having undergone surgery (1998-2012) and postoperatively treated and monitored at Split University Hospital Center, whose tissue samples were stored at Department of Pathology, Split University Hospital Center, were included in the study. Survival time was analyzed with Kaplan-Meier method and the log-rank test was used to assess between-group differences. Cox proportional hazard regression model was used on multivariate survival analysis. Patients were followed from the time of primary surgery until death or last follow up in December 2015. Results: Women with serous and clear cell endometrial cancer had similar survival compared to those with high-grade endometrioid endometrial cancer. On multivariate analysis, only earlier stage was an independent predictor of improved survival. Conclusions: The present findings suggest that serous and clear cell endometrial carcinomas have a similar prognosis compared to high-grade endometrioid carcinoma of the uterus.

Uterine cancer; High-grade endometrial cancer; Serous endometrial cancer; Clear cell endometrial cancer; Survival.

[1] Memon A. “Epidemiology of gynaecological cancers“. In: Shafi M., Earl H., Tan L., (eds). Gyneaecological oncology. Cambridge: Cambridge University Press, 2010, 1.

[2] Hacker N., Friedlander M.: “Uterine cancer“. In: Berek J., Hacker N., (eds). Berek and Hacker’s Gynaecology. 5th ed. Baltimore: Lippincott Wiliams & Wilkins, 2010, 396.

[3] Bockman J.V.: “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol., 1983, 15, 10.

[4] Homesley H.D.: “Present status and future direction of clinical trials in advanced endometrial carcinoma”. J. Gynecol Oncol., 2008, 19, 157.

[5] Creasman W.: “Adenocarcinoma of the uterus“. In: DiSaia P., Creasman W., (eds). Clinical gynecologic oncology. 7th ed. St. Louis: Mosby, 2007, 147.

[6] Cirisano F.D. Jr., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S., et al.: “Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma”. Gynecol. Oncol., 1999, 74, 385.

[7] Voss M.A., Ganesan R., Ludeman L., McCarthy K., Gornall R., Schaller G., et al.: “Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation:”. Gynecol. Oncol., 2012, 124, 15.

[8] Hendrickson M.R., Ross J., Eifel P., Martinez A., Kempson R.: “Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma”. Am. J. Surg. Pathol., 1982, 6, 93.

[9] Carcangiu M.L., Chambers J.T.: “Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma”. Gynecol. Oncol., 1992, 47, 298.

[10] Slomovitz B.M., Burke T.W., Eifel P.J., Ramondetta L.M., Silva E.G., Jhingran A., et al.: “Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases”. Gynecol. Oncol., 2003, 91, 463.

[11] Acharya S., Hensley M.L., Montag A.C., Fleming G.F.: “Rare uterine cancers”. Lancet Oncol., 2005, 6, 61.

[12] Goff B.A., Kato D., Schmidt R.A., Ek M., Ferry J.A., Muntz H.G., et al.: “Uterine papillary serous carcinoma: patterns of metastatic spread”. Gynecol Oncol., 1994, 54, 264.

[13] Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., et al.: “Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2013, 24, 33.

[14] Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A., et al.: “Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers”. Br. J. Cancer, 2006, 94, 642. [15] Boruta D.M., Gehrig P.A., Groben P.A., Bae-Jump V., Boggess J.F., Fowler W.C. Jr., Van Le L.: “Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer, 2004, 101, 2214.

[16] Alkushi A., Kobel M., Kalloger S.E., Gilks C.B.: “High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes”. Int. J. Gynecol. Pathol., 2010, 29, 343.

[17] Greggi S., Mangili G., Scaffa C., Scala F., Losito S., Iodice F., et al.: “Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study”. Int. J. Gynecol. Cancer, 2011, 21, 661.

[18] Soslow R.A., Bissonnette J.P., Wilton A., Ferguson S.E., Alektiar K.M., Duska L.R., Oliva E.: “Clinicopathologic analysis of 187 high grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences”. Am. J. Surg. Pathol., 2007, 31, 979.

[19] Cirisano F.D. Jr., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S., et al.: “The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma”. Gynecol. Oncol., 2000, 77, 55.

[20] Alektiar K.M., McKee A., Lin O., Venkatraman E., Zelefsky M.J., McKee B., et al.: “Is there a difference in outcome between stage III endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?” Int. J. Radiat. Oncol. Biol. Phys., 2002, 54, 79.

[21] Halperin R., Zehavi S., Langer R., Hadas E., Bukovsky I., Schneider D.: “Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study”. Eur. J. Gynaecol. Oncol., 2002, 23, 300.

[22] Creasman W.T., Kohler M.F., Odicino F., Maisonneuve P., Boyle P.: “Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium”. Gynecol. Oncol., 2004, 95, 593.

[23] Ueda S.M., Kapp D.S., Cheung M.K., Shin J.Y., Osann K., Husain A., et al.: “Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths”. Am. J. Obstet. Gynecol., 2008, 198, 218.

[24] Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., et al.: “Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, 105. [25] Johnson N., Bryant A., Miles T., Hogberg T., Cornes P.: “Adjuvant chemotherapy for endometrial cancer afterhysterectomy”. Cochrane Database Syst. Rev., 2011, CD003175.

[26] Reynaers E.A., Ezendam N.P., Pijnenborg J.M.: “Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer”. J. Surg. Oncol., 2015, 111, 790.

[27] McGunigal M., Liu J., Kalir T., Chadha M., Gupta V.: “Surrvival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers”. Int. J. Gynecol. Cancer, 2017, 27, 85.

[28] Vance S., Yechieli R., Cogan C., Hanna R., Munkarah A., Elshaikh M.A.: “The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma”. Gynecol. Oncol., 2012, 126, 16.

[29] Galaal K., Al Moundhri M., Bryant A., Lopes A.D., Lawrie T.A.: “Adjuvant chemotherapy for advanced endometrial cancer”. Cochrane Database Syst Rev., 2014, CD010681.

[30] Srdelić Mihalj S., Kuzmić-Prusac I., Zekić-Tomaš S., Šamija-Projić I., Čapkun V.: “Lipocalin-2 and matrix metalloproteinase-9 expression in high-grade endometrial cancer and their prognostic value”. Histopathol., 2015, 67, 206.